

**Can't Stop, Won't Stop the Search for Relief: Scratching the Surface of Itch  
& Inflammation in Moderate-to-Severe Atopic Dermatitis  
Tweeterial #2 Reference List**

**Tweet #2:**

Wei W, Ghorayeb E, Andria M, et al. *Ann Allergy Asthma Immunol*. 2019;123(4):381-388.e2.

**Tweet #4:**

Renert-Yuval Y, Guttman-Yassky E. New treatments for atopic dermatitis targeting beyond IL-4/IL-13 cytokines. *Ann Allergy Asthma Immunol*. 2020;124(1):28-35.

**Tweet #5:**

Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. *Lancet*. 2017 Jun;389(10086):2287-2303.  
Simpson EL, Bieber T, Guttman-Yassky E, et al. Two Phase 3 trials of dupilumab versus placebo in atopic dermatitis. *N Engl J Med*. 2016;375:2335-2348.

**Tweet #6:**

Beck LA, Silverberg JI, Simpson EL, et al. Dupilumab significantly improves sleep outcomes in adult patients with atopic dermatitis: results from five randomized clinical trials. *J Eur Acad Dermatol Venereol*. 2020 Aug 12. Online ahead of print. doi:10.1111/jdv.16865.

Silverberg JI, Yosipovitch G, Simpson EL, et al. Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS. *J Am Acad Dermatol*. 2020;82(6):1328-1336.

**Tweet #7:**

Alexis AF, Rendon M, Silverberg JI, et al. Efficacy of dupilumab in different racial subgroups of adults with moderate-to-severe atopic dermatitis in three randomized, placebo-controlled phase 3 trials. *J Drug Dermatol*. 2019 Aug;18(8):804-813.

**Tweet #8:**

Ou Z, Chen C, Chen A, Yang Y, Zhou W. Adverse events of dupilumab in adults with moderate-to-severe dermatitis: A meta-analysis. *Int Immunopharmacol*. 2018 Jan;54:303-310.

**Tweet #9:**

Ou Z, Chen C, Chen A, Yang Y, Zhou W. Adverse events of dupilumab in adults with moderate-to-severe dermatitis: A meta-analysis. *Int Immunopharmacol*. 2018 Jan;54:303-310.

**Tweet #11:**

Kabashima K, Matsumura T, Komazaki H, Kawashima M for the Nemolizumab -JP01 Study Group. Trial of nemolizumab and topical agents for atopic dermatitis with pruritus. *N Engl J Med*. 2020;383:141-150; 2020. Nemolizumab For Atopic Dermatitis [video].

**Tweet #12:**

Silverberg JI, Toth D, Bieber T, et al. Tralokinumab plus Topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: Results from The double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial\*. *British Journal of Dermatology*. 2021;184(3):450-463. doi:10.1111/bjd.19573

Wollenberg A, Blauvelt A, Guttman-Yassky E, et al. Tralokinumab for moderate-to-severe atopic dermatitis: Results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 And ECZTRA 2)\*. *British Journal of Dermatology*. 2020;184(3):437-449. doi:10.1111/bjd.19574